GPU acceleration of Dock6's Amber scoring computation.

Adv Exp Med Biol

Department of Computer Science and Engineering, Sino-German Joint Software Institute, Beihang University, 100191 Beijing, China.

Published: February 2011

Dressing the problem of virtual screening is a long-term goal in the drug discovery field, which if properly solved, can significantly shorten new drugs' R&D cycle. The scoring functionality that evaluates the fitness of the docking result is one of the major challenges in virtual screening. In general, scoring functionality in docking requires a large amount of floating-point calculations, which usually takes several weeks or even months to be finished. This time-consuming procedure is unacceptable, especially when highly fatal and infectious virus arises such as SARS and H1N1, which forces the scoring task to be done in a limited time. This paper presents how to leverage the computational power of GPU to accelerate Dock6's (http://dock.compbio.ucsf.edu/DOCK_6/) Amber (J. Comput. Chem. 25: 1157-1174, 2004) scoring with NVIDIA CUDA (NVIDIA Corporation Technical Staff, Compute Unified Device Architecture - Programming Guide, NVIDIA Corporation, 2008) (Compute Unified Device Architecture) platform. We also discuss many factors that will greatly influence the performance after porting the Amber scoring to GPU, including thread management, data transfer, and divergence hidden. Our experiments show that the GPU-accelerated Amber scoring achieves a 6.5× speedup with respect to the original version running on AMD dual-core CPU for the same problem size. This acceleration makes the Amber scoring more competitive and efficient for large-scale virtual screening problems.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123368PMC
http://dx.doi.org/10.1007/978-1-4419-5913-3_56DOI Listing

Publication Analysis

Top Keywords

amber scoring
16
virtual screening
12
scoring
8
scoring functionality
8
nvidia corporation
8
compute unified
8
unified device
8
device architecture
8
amber
5
gpu acceleration
4

Similar Publications

Objectives: Dementia, a growing concern globally, affects more than 55 million people-a number projected to rise to 152 million by 2050. Current medications target Alzheimer's disease, the most prevalent form of dementia. This study investigated L.

View Article and Find Full Text PDF

Purpose/aim Of The Study: There is limited real-world evidence regarding the effectiveness and safety of dupilumab in Gulf countries. The study aimed to evaluate atopic dermatitis (AD) disease control in adult and adolescent patients (≥12 years) treated with dupilumab in Gulf countries.

Materials And Methods: This observational study included patients with moderate-to-severe AD who initiated dupilumab within 30 days.

View Article and Find Full Text PDF

Post-acute sequela of COVID-19 infection in individuals with multiple sclerosis.

Mult Scler

January 2025

Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.

Background: Many common symptoms in post-acute sequelae following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) overlap with those of multiple sclerosis (MS). We examined symptoms and performance of the PASC score, developed in the general population, in MS based on infection history.

Methods: We surveyed North American Research Committee on Multiple Sclerosis (NARCOMS) registry participants regarding infections and categorized participants based on infection history.

View Article and Find Full Text PDF

Risk assessments are important tools to identify deficits in biosecurity management practices. A major strength of some existing tools is that they facilitate cross-country comparisons. However, a weakness is their failure to account for unique intra-national farming enterprise structures such as, for example, pasture-based dairying.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!